| 1.1 Participant‐reported global improvement in symptoms (0 to 100 VAS reduction) |
7 |
176 |
Mean Difference (IV, Random, 95% CI) |
‐2.22 [‐10.48, 6.04] |
| 1.1.1 Children only |
2 |
30 |
Mean Difference (IV, Random, 95% CI) |
‐11.92 [‐39.34, 15.49] |
| 1.1.2 Other (adults only or adults and children) |
5 |
146 |
Mean Difference (IV, Random, 95% CI) |
0.98 [‐5.47, 7.42] |
| 1.2 Parent assessment at end of treatment (VAS) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.3 Parents global improvent in eczema symptoms at 8 weeks |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.4 Physician‐reported global improvement in symptoms (0 to 100 VAS reduction) |
8 |
289 |
Mean Difference (IV, Random, 95% CI) |
‐3.26 [‐6.96, 0.45] |
| 1.4.1 Children only |
3 |
101 |
Mean Difference (IV, Random, 95% CI) |
‐2.94 [‐9.18, 3.30] |
| 1.4.2 Other (adults only or adults and children) |
5 |
188 |
Mean Difference (IV, Random, 95% CI) |
‐3.39 [‐8.12, 1.33] |
| 1.5 Physician assessment at the end of treatment (VAS ‐ MD) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.6 Physician‐reported improvement in symptoms (VAS 0 to 50) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.7 Physician‐reported assessment at end of treatment (0 to 3 scale): high‐dose |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.8 Physician‐reported assessment at end of treatment (0 to 3 scale): low‐dose |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.9 Physician‐reported assessment at end of treatment (total disease scores) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.10 Physician‐reported improvement in Leicester scores |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.11 Physician‐reported assessment at end of treatment (VAS 0 to 100) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.12 Dermatology Life Quality Index (DLQI) at the end of treatment |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.13 Adverse events |
4 |
264 |
Risk Ratio (M‐H, Random, 95% CI) |
0.97 [0.71, 1.33] |
| 1.14 Adverse event (minor signs or symptoms) |
3 |
172 |
Risk Ratio (M‐H, Random, 95% CI) |
1.00 [0.64, 1.57] |
| 1.15 Concurrent treatment (emollient cream) (kg) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
| 1.16 Concurrent treatment (topical steroid) (kg) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
